Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

Joseph A. Sparano, Molin Wang, Silvana Martino et al. · New England Journal of Medicine · 2008 · 1K citations · Full text

Medicine, Oncology, Pharmacology +13

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

Edmund A. Gehan · Journal of Chronic Diseases · 1961 · 670 citations

Medicine, Oncology, Pharmacology +3

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Andrew D. Seidman, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2008 · 604 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Stephen E. Jones, John K. Erban, Beth Overmoyer et al. · Journal of Clinical Oncology · 2005 · 547 citations · Full text

Medicine, Oncology, Pharmacology +14